Peripheral Arterial Disease (PAD) Drug Development Pipeline Analysis Report 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jul 30, 2018--The “2018 Peripheral Arterial Disease (PAD) Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Peripheral Arterial Disease (PAD) Market” report has been added to ResearchAndMarkets.com’s offering.
Peripheral Arterial Disease is a condition in which plaque or fatty deposits build up in the arteries which supply blood to the leg muscles. It can cause serious implications such as myocardial infarction, vascular dementia, stroke etc. An estimated 0.2 billion population is affected worldwide and the market size of Peripheral Arterial Disease (PAD) is estimated to be around $4.5 billion.
To assist researchers, investors and business development managers, the publisher has come up with a comprehensive report on Peripheral Arterial Disease pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials. Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Peripheral Arterial Disease (PAD) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
Companies Mentioned480 Biomedical, Inc. Alucent Medical Inc Anaeropharma Science, Inc. AnGes MG Inc AngioSoma Inc apceth Biopharma GmbH Athera Biotechnologies AB Athersys Inc Bayer AG Betagenon AB BiogenCell Ltd CardioVascular BioTherapeutics Inc Celularity Inc Exodos Life Sciences LP Foresee Pharmaceuticals Co Ltd Hemostemix Inc ID Pharma Co Ltd Juventas Therapeutics Inc LipimetiX Development Inc MultiGene Vascular Systems (MGVS) Ltd Nangiotx Inc Novartis AG Nuo Therapeutics Inc Pluristem Therapeutics Inc. G. Pohl-Boskamp GmbH & Co. KG Proteon Therapeutics Inc Resverlogix Corporation Reven Pharmaceuticals Inc RHEACELL GmbH & Co. KG SK Chemicals Co.,Ltd Stemedica Cell Technologies Inc Symic Biomedical Inc VESSL Therapeutics Ltd ViroMed Co Ltd Yuyu Pharma Inc
Key Topics Covered:
1 Table of Contents
2 Peripheral Arterial Disease (PAD) Pipeline Analysis
3 Peripheral Arterial Disease (PAD)- Company Wise Pipeline Analysis
4 Peripheral Arterial Disease (PAD) R&D Pipeline Snapshots
5 Recent Developments in Peripheral Arterial Disease (PAD) Pipeline
For more information about this report visit https://www.researchandmarkets.com/research/qpt2t6/peripheral?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180730005341/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Drug Discovery,Cardiovascular Drugs ,Clinical Trials
INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 07/30/2018 07:25 AM/DISC: 07/30/2018 07:25 AM